rethinkPeptides Search
Menu
Study breakdown

MRI Study Shows Rimegepant Treats Migraine Without Constricting Brain Blood Vessels

evidence
The takeaway

Longitudinal MRI angiography confirms rimegepant treats migraine attacks without constricting cerebral or extracerebral arteries, unlike triptans, making it safe for patients with vascular disease.

No vasoconstriction on MRA

First direct evidence that rimegepant doesn't constrict brain arteries during migraine attacks

What the researchers found

Rimegepant effectively treats migraine without constricting cerebral or extracerebral arteries, as demonstrated by longitudinal MRI angiography during spontaneous attacks.

Why it matters

This is the first direct proof that rimegepant doesn't constrict brain blood vessels during actual migraine attacks — critical safety evidence for the millions of migraine patients who can't use triptans due to heart disease or stroke risk.

How the study worked

Prospective, longitudinal study using magnetic resonance angiography at a single academic imaging centre to measure arterial diameter during migraine attacks.

What this study cannot tell us

Single academic center; likely small sample size given the logistical challenge of capturing spontaneous migraine attacks on MRI; may not represent all migraine subtypes.

How to read the evidence

Prospective longitudinal imaging study — strong mechanistic evidence but likely small sample size due to logistical constraints.

When this study was published

Published in 2026, providing the first direct vascular imaging evidence for CGRP antagonists during spontaneous migraine.

The bigger picture

Confirming the non-vasoconstrictive mechanism of CGRP antagonists opens migraine treatment to millions of patients with cardiovascular disease who were previously left without effective options.

Questions still open

  • Can rimegepant be recommended as first-line acute treatment for migraine patients with cardiovascular risk factors?
  • Does the lack of vasoconstriction mean CGRP antagonists work through entirely different mechanisms than triptans?

Common questions

Why can't some migraine patients use triptans?
Triptans constrict blood vessels, which can be dangerous for people with heart disease, prior stroke, or uncontrolled high blood pressure. This leaves millions of migraine sufferers without effective treatment options.
Does this study prove rimegepant is safe for the heart?
It directly shows rimegepant doesn't constrict brain arteries during migraine — a key safety advantage over triptans. Combined with clinical trial data, this strongly supports its cardiovascular safety profile.

Read the original research

Investigation of the rimegepant effect on cerebral and extracerebral arteries during migraine attacks: a longitudinal magnetic resonance angiography study.

Brain communications, 8(1), fcag004

Citation

Chaudhry, Basit Ali; Younis, Samaira; Al-Mashat, Hassan; Gozalov, Emil; Amin, Tariq Mohammad; de Koning, Patrick J H; Larsson, Henrik Bo Wiberg; Amin, Faisal Mohammad. (2026). Investigation of the rimegepant effect on cerebral and extracerebral arteries during migraine attacks: a longitudinal magnetic resonance angiography study.. Brain communications, 8(1), fcag004. https://doi.org/10.1093/braincomms/fcag004